IBS as a functional diagnosis — and its limitations
The diagnosis of IBS (irritable bowel syndrome) is made clinically using the Rome criteria and by definition requires the absence of structural or biochemical explanation. It is, in other words, a diagnosis of exclusion — and that is precisely where the problem begins.
Conventional workup excludes structural pathology: colorectal cancer, IBD, coeliac disease. It does not, however, exclude the functional biological mechanisms that drive the majority of IBS cases. The SIBO breath test, GI Effects® stool panel, and ALCAT test are not part of standard IBS workup — and that is exactly why so many patients remain in a diagnostic limbo for years.
"A negative gastroscopy and colonoscopy rules out SIBO, dysbiosis, intestinal hyperpermeability, and food intolerance in exactly the same way a chest X-ray rules out anxiety — it doesn't."
Mechanism 1 — SIBO and the small intestinal picture
Small Intestinal Bacterial Overgrowth (SIBO) is arguably the most underdiagnosed cause of IBS-like symptoms in clinical practice. The mechanism is specific: colonic bacteria migrate upward into the small intestine, compete for nutrients, and produce hydrogen and methane gas that generate characteristic bloating, gas, and altered gut motility.
Pimentel's meta-analysis (2000) demonstrated SIBO prevalence of 78% in the IBS population. Critically: SIBO cannot be excluded by a normal GI Effects® stool panel — the two tests measure fundamentally different segments of the gut with fundamentally different methodology. The breath test is mandatory when SIBO is suspected.
Clinical predictors of SIBO in IBS
- Bloating that progresses throughout the day, worst by evening
- Gas and pain 60–120 minutes after eating (fermentation time)
- History of gut infections or gastroenteritis
- Predominantly upper gastrointestinal symptoms
- Symptom improvement with antibiotic treatment
- Rosacea or skin problems concurrent with gut symptoms
Mechanism 2 — gut microbiome dysbiosis
GI Effects® Comprehensive Stool Profile identifies abnormalities in the large intestinal microbiome using quantitative PCR technology. In IBS we typically observe: reduced species diversity (Shannon index), altered Firmicutes/Bacteroidetes ratio, impaired production of short-chain fatty acids (SCFA) — particularly butyrate — and elevated inflammatory markers such as calprotectin.
Butyrate deficiency is clinically central: butyrate is the primary energy source for colonocytes, modulates tight junction integrity in the gut epithelium, and exerts anti-inflammatory effects via NF-κB inhibition. Patients with IBS and low butyrate production frequently exhibit both intestinal hyperpermeability and low-grade mucosal inflammation without meeting IBD criteria.
Mechanism 3 — food intolerance and intestinal permeability
Non-IgE-mediated food intolerance differs fundamentally from IgE-mediated allergy. It does not involve mast cell degranulation and does not produce acute reactions — instead it triggers a delayed cellular immune response that may take 2–72 hours to manifest as gut symptoms, making causality extremely difficult to identify without structured testing.
The ALCAT test measures neutrophil and monocyte reactivity to food antigens via impedance measurement. It identifies individual food intolerances at the cellular level — not antibodies — and is the only test that directly measures the immunological response driving delayed reactions.
Zonulin, measured as part of GI Effects®, is the best-validated marker of intestinal hyperpermeability. Elevated zonulin indicates that tight junctions in the gut epithelium are compromised — a state that permits passage of bacterial LPS fragments and incompletely digested food proteins into submucosal tissue and systemic circulation.
The combination of elevated zonulin + positive ALCAT is a common finding in complex IBS that has not responded to standard management. Zonulin tells you the barrier is leaking; ALCAT identifies which foods are driving the immune activation. An elimination protocol based on ALCAT results combined with barrier restoration (L-glutamine, butyrate, collagen) produces significant symptom reduction in this subgroup — typically within 6–8 weeks.
Mechanism 4 — vagus nerve and the gut-brain axis
The vagus nerve carries 80% of signals in the gut-brain axis — from gut to brain, not the reverse. In IBS, reduced vagal tone (measured as HRV), altered gastric emptying rate, and dysregulated serotonin signalling in the gut (95% of the body's serotonin is in the gastrointestinal tract) are consistently observed.
Vagal dysregulation explains why psychological stress worsens IBS — not via a psychosomatic mechanism, but via direct neurobiological effects on gut motility, secretion patterns, and visceral pain sensitivity. HRV analysis can quantify vagal tone and serves as a biomarker for autonomic nervous system function.
If you have been given a diagnosis of IBS but have never been tested for SIBO with a breath test, never had a stool panel measuring your gut microbiome, and never investigated food intolerance systematically — you have not had a complete workup. You have received a label that describes your symptoms but does not explain why you have them.
The biology behind IBS is measurable. And if it is measurable, it can be treated specifically — not with generic dietary advice, but with a protocol matched to your particular biological subgroup.
Workup protocol — clinical sequencing
Sequence matters. In clinical practice with IBS patients, the following sequence is recommended:
- Step 1: GI Effects® Comprehensive — provides a baseline picture of microbiome, inflammation, barrier function, and digestion. Identifies whether SIBO follow-up is indicated (reduced sIgA suggests impaired gut immunity and increased SIBO risk).
- Step 2: SIBO breath test — if GI Effects shows a pattern consistent with small intestinal involvement, or if the clinical picture is dominated by upper GI symptoms.
- Step 3: ALCAT — if GI Effects shows elevated zonulin, if elimination diets have previously produced symptom reduction, or if the symptom pattern is difficult to periodise.
- Step 4: Organix® — if systemic symptoms (brain fog, fatigue, skin problems) dominate alongside gut complaints. Organix measures whether gut dysbiosis is driving metabolic disturbance at a systemic level.